Le cancer de l'endomètre MSI-H/dMMR (~25-30% des cas avancés) est admissible à un régime fondé sur l'ICI...
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
| ID | BMA-MSI-STATUS-ENDOMETRIAL |
|---|---|
| Type | Pertinence thérapeutique |
| État | reviewed 2026-05-07 | actionability review required |
| Maladies | DIS-ENDOMETRIAL |
| Sources | SRC-ESMO-ENDOMETRIAL-2022 SRC-NCCN-UTERINE-2025 |
Faits relatifs à l ' action en justice
| Biomarqueur | BIO-MSI-STATUS |
|---|---|
| Variante | MSI-H |
| Maladie | DIS-ENDOMETRIAL |
| Niveau ESCAT | IA |
| Combinaisons recommandées | dostarlimab + carboplatin + paclitaxel (dMMR/MSI-H 1L per SRC-NCCN-UTERINE-2025), pembrolizumab + carboplatin + paclitaxel (dMMR/MSI-H 1L per SRC-NCCN-UTERINE-2025), pembrolizumab monotherapy (MSI-H 2L+ per SRC-ESMO-ENDOMETRIAL-2022) |
| Résumé des faits | MSI-H/dMMR endometrial cancer (~25-30% of advanced cases) qualifies for ICI-based regimens. Dostarlimab + carboplatin + paclitaxel 1L (RUBY trial; mOS NR vs 36.7 mo, HR 0.64 in dMMR/MSI-H subgroup; FDA-approved 2023). Pembrolizumab + carboplatin + paclitaxel 1L (KEYNOTE-868/NRG-GY018; FDA-approved 2023 for dMMR/MSI-H). Also pembrolizumab monotherapy 2L+ for MSI-H/dMMR endometrial (KEYNOTE-158; FDA-approved 2017 tumor-agnostically). MSI/MMR testing mandatory at diagnosis of advanced/recurrent endometrial cancer per NCCN/ESMO. Indication selection enforced by algorithm layer (IND-ENDOMETRIAL-DMMR); this BMA surfaces ESCAT context only. |
Notes
Variant_qualifier "MSI-H" matches positive MSI-H patient values. RUBY (SRC-RUBY) and KEYNOTE-868 source stubs not yet ingested — citing NCCN/ESMO as proxies. BIO-DMMR-IHC BMAs cover the IHC-based pathway; this entry covers the PCR/NGS-based MSI result as an equivalent eligibility input.
Utilisé par
No reverse references found in the YAML corpus.